Clinical Trial Update: Phase I Study to Assess the Absorption, Metabolism, and Excretion of [14C] Labeled SPN-810M [Phase 1]

View source ↗

Summary

Phase I study to assess absorption, metabolism, and excretion of [14C] labeled SPN-810M in individuals with impulsive aggression comorbid with ADHD; study statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• SPN-810M (viloxazine)

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Impulsive Aggression Comorbid With ADHD | Phase 1 | Status: COMPLETED